Connective Tissue Growth Factor Fragments and Methods and Uses Thereof

a technology of connective tissue and growth factor, which is applied in the field of growth factor fragments, can solve the problems that ctgf alone cannot induce this property in fibroblasts, and achieve the effects of suppressing, increasing the activity of ctgf fragments, and inhibiting or suppressing the activity of ctg

Inactive Publication Date: 2010-07-29
UNIV OF MIAMI
View PDF18 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0020]The present invention also provides pharmaceutical compositions comprising the CTGF fragments of the present invention. Such compositions may be useful in wound healing, bone and tissue repair, wherein the increased activity of CTGF is desirable.

Problems solved by technology

As reported in the art, although TGF-β can stimulate the growth of normal fibroblasts in soft agar, CTGF alone cannot induce this property in fibroblasts.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Connective Tissue Growth Factor Fragments and Methods and Uses Thereof
  • Connective Tissue Growth Factor Fragments and Methods and Uses Thereof
  • Connective Tissue Growth Factor Fragments and Methods and Uses Thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

CTGF Fragments Stimulate Extracellular Matrix Synthesis

[0157]To prepare CTGF fragments, human recombinant CTGF (full length) was digested by chymotrypsin to render one CTGF fragment. Recombinant CTGF fragments were also produced by expressing either or both exon 2 and exon 3 of CTGF. A continuous line of cultured normal rat kidney (NRK) fibroblasts, designated as clone NRK-49F, were obtained from the American Type Culture Collection (ATCC) to produce cell cultures. Human foreskin fibroblasts were established from explant cultures. Cell cultures were maintained in Dulbecco's modified eagle media (DME) containing 2.5% fetal bovine serum and 2.5% Nu-Serum I (Collaborative Biomedical Products, Bedford, Mass.) and passaged prior to confluence.

[0158]To examine fibroblast collagen synthesis, growth-arrested monolayers of NRK and human foreskin fibroblasts were prepared by seeding 10,000 cells / well in 48 well plates and allowing the cells to grow to confluence in 5 to 7 days in DME and 2.5%...

example 2

CTGF Fragments Induce Myofibroblast Differentiation

[0159]The CTGF fragments and cell cultures were prepared as described above. To examine induction of myofibroblasts by CTGF fragments, growth-arrested monolayers of NRK for foreskin fibroblasts were prepared and treated as described above. Following treatments, 48-well plate monolayers were washed twice with TBS and fixed in methanol at −20 degrees C. for 10 minutes before processing for immunohistological detection of alpha-smooth muscle. Immunohistological detection was conducted. Following fixation, cell monolayers were washed twice with TBS and blocked for 30 minutes with 10% horse serum / 2% milk in TBS. The cells were then incubated for 1 hour with monoclonal mouse anti alpha-smooth muscle actin IgG (Clone 1A4, Sigma Chemical) at a 1:200 dilution in horse serum / milk / TBS. Following three washes with TBS, cell monolayers were then incubated for 1 hour with biotinlyated horse anti-mouse IgG (Vector Labs, Burlingame, Calif.) at a 1:...

example 3

Neutralizing Anti-CTGF Antibodies Block TGF-B Induced DNA Synthesis, Collagen Synthesis, and Myofibroblast Induction

[0161]Specific anti-CTGF antibodies were raised against biologically active recombinant human CTGF produced in a baculovirus expression system using methods known in the art. The antibodies were prepared in goats and tested for neutralization activity of CTGF directly or on TGF-induced DNA or collagen synthesis in NRK fibroblasts. The goat antibodies exhibited activity in the assays for neutralization of TGF-13 action. In these assays, the goat anti-CTGF antibodies were able to block DNA synthesis. In addition, as demonstrated in FIG. 5, CTGF antibodies were able to block collagen synthesis and myofibroblast formation induced by TGF-β. It was noted that the amount of antibody required to block collagen synthesis was significantly less than the amount needed to block DNA synthesis. Both western Mot assay, and competition ELISA assays indicated that most of the antibodie...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
concentrationaaaaaaaaaa
Concentrationsaaaaaaaaaa
Login to view more

Abstract

The present invention is directed to CTGF fragments comprising at least exon 2 or exon 3 of CTGF and having the ability to induce extracellular matrix synthesis, in particular, collagen synthesis and myofibroblast differentiation. The present invention is further directed to methods using said CTGF fragments to identify compositions which modulate the activity of said CTGF fragments and to the compositions so identified. The invention also relates to methods of treating CTGF-associated disorders and diseases associated with the overproduction of the extracellular matrix.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional application of U.S. application Ser. No. 10 / 315,568 filed Dec. 9, 2002, now pending; which is a divisional application of U.S. application Ser. No. 09 / 461,688 filed Dec. 14, 1999, now issued as U.S. Pat. No. 6,492,129; which claims the benefit under 35 USC§119(e) to U.S. Application Ser. No. 60 / 112,241 filed Dec. 14, 1998, now abandoned and to U.S. Application Ser. No. 60 / 112,240 filed Dec. 14, 1998, now abandoned. The disclosure of each of the prior applications is considered part of and is incorporated by reference in the disclosure of this application.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]This invention relates generally to the field of growth factors and specifically to fragments of Connective Tissue Growth Factor (CTGF) and methods of use thereof.[0004]2. Background Information[0005]Growth Factors. Growth factors can be broadly defined as multifunctional, locally acting intra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7088C07H21/04C12N15/09A61K31/7105A61K38/00A61K38/04A61K39/395A61K45/00A61K48/00A61P1/16A61P3/10A61P9/00A61P9/10A61P9/12A61P9/14A61P11/00A61P13/12A61P17/00A61P17/02A61P19/02A61P19/04A61P27/02A61P29/00A61P35/00A61P35/04A61P37/02A61P43/00C07K14/47C07K14/475C07K14/50C07K16/22C12Q1/02G01N33/15G01N33/50G01N33/566
CPCA61K38/00A61K48/00C07K16/22C07K14/475A61K2039/505A61P1/16A61P11/00A61P13/00A61P13/12A61P17/00A61P17/02A61P19/02A61P19/04A61P27/02A61P29/00A61P35/00A61P35/04A61P37/02A61P43/00A61P9/00A61P9/10A61P9/12A61P9/14A61P3/10
Inventor GROTENDORST, GARY R.
Owner UNIV OF MIAMI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap